VIEW MOREUnder the review spotlight: current insights into the molecular bases of gastric cancer, targeted treatment strategies in the pipeline, and future therapeutic opportunities
VIEW MOREVHIO establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery
VIEW MOREVHIO-led research unveils a novel microprotein as a critical regulator of epithelial cell identity with tumor suppressor activity
Latest News
25 November 2022
Under the review spotlight: current insights into the molecular bases of gastric cancer, targeted treatment strategies in the pipeline, and future therapeutic opportunities
Recently published in Nature Reviews Gastroenterology & Hepatology*, a comprehensive Review focused on gastric cancer and gastro-oesophageal junction cancer (GC-GOJC)...
24 November 2022
VHIO establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery
Recently published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), VHIO investigators have established...
16 November 2022
VHIO-led research unveils a novel microprotein as a critical regulator of epithelial cell identity with tumor suppressor activity
Results of a study led by María Abad, Principal Investigator of VHIO’s Cellular Plasticity and Cancer Group, identify a new...
15 November 2022
Reflective of their contributions to cancer science and medicine, VHIO’s Josep Tabernero and Enriqueta Felip feature among Clarivate’s Highly Cited Researchers 2022
Published today, Clarivate has revealed its annual #HighlyCited2022 researchers list. Featuring among the world’s elite scientists at academic research institutes and...
Research Programs
PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group
Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group
We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).
CORE TECHNOLOGIES
Cancer Genomics Group
VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.
PRINCIPAL RESEARCHERS
Events
Thursday 15 December 22 - 11:00 AM
Patients
Maternity and cancer: how to face the disease during pregnancy, postpartum and raising of our children
Thursday 15 December 22 - 04:00 PM
scientific-seminars
Bruno Di Stefano | Dissecting mechanisms that govern cellular identity
Thursday 15 December 22 - 11:00 AM
Patients
How to learn to love yourself after cancer. Emotional management tools. Workshop 1
Thursday 15 December 22 - 04:00 PM
scientific-seminars
Bruno Di Stefano I Defining the Role of RNA Sequestration in Oncogenesis
